Lymphatic targeting of cilnidipine by designing and developing a nanostructured lipid carrier drug delivery system.

Objective: The objective of current research is to design, develop, and optimize a cilnidipine (CLN) nanostructured lipid carrier (NLC)-based drug delivery system for the effective treatment of hypertension (HT).

Significance: Oral administration of CLN-loaded NLC (CLN NLC) containing glyceryl monostearate (GMS) as a solid and isopropyl myristate (IPM) as a liquid lipid may show remarkable lymphatic uptake through payer patches.

Methods: The emulsification probe sonication technique was used followed by optimization using 3 factorial designs.